CN1194722C - 治疗肝炎的舒肝止痛膏 - Google Patents
治疗肝炎的舒肝止痛膏 Download PDFInfo
- Publication number
- CN1194722C CN1194722C CNB021154678A CN02115467A CN1194722C CN 1194722 C CN1194722 C CN 1194722C CN B021154678 A CNB021154678 A CN B021154678A CN 02115467 A CN02115467 A CN 02115467A CN 1194722 C CN1194722 C CN 1194722C
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- hepatitis
- vegetable oil
- weight portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 24
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 22
- 239000000284 extract Substances 0.000 title claims description 27
- 239000003814 drug Substances 0.000 claims abstract description 38
- 239000000843 powder Substances 0.000 claims abstract description 16
- 239000004863 Frankincense Substances 0.000 claims abstract description 15
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 14
- 239000008158 vegetable oil Substances 0.000 claims abstract description 14
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 10
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003921 oil Substances 0.000 claims abstract description 10
- 235000019198 oils Nutrition 0.000 claims abstract description 10
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 9
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 3
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 3
- 239000002674 ointment Substances 0.000 claims description 15
- 241000717739 Boswellia sacra Species 0.000 claims description 14
- 241000283956 Manis Species 0.000 claims description 9
- 241001057584 Myrrha Species 0.000 claims description 9
- 235000008216 herbs Nutrition 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- 238000006062 fragmentation reaction Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000005336 cracking Methods 0.000 claims description 2
- 238000013467 fragmentation Methods 0.000 claims description 2
- 150000002333 glycines Chemical class 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000002893 slag Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 210000004185 liver Anatomy 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 239000011505 plaster Substances 0.000 abstract description 6
- 230000036407 pain Effects 0.000 abstract description 5
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract description 2
- 241000202726 Bupleurum Species 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 7
- 238000002791 soaking Methods 0.000 abstract 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 241000270666 Testudines Species 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 description 18
- 208000019425 cirrhosis of liver Diseases 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 241000700721 Hepatitis B virus Species 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 201000001352 cholecystitis Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 206010019847 hepatosplenomegaly Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 210000001113 umbilicus Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 102000007501 Thymosin Human genes 0.000 description 2
- 108010046075 Thymosin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- 230000007866 hepatic necrosis Effects 0.000 description 2
- 201000010284 hepatitis E Diseases 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229930192484 Skullcapflavone Natural products 0.000 description 1
- CZRGNFVQUYWGKP-UHFFFAOYSA-N Skullcapflavone I Natural products COC=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1O CZRGNFVQUYWGKP-UHFFFAOYSA-N 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000293 acute skin toxicity Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000008361 herbal raw material Substances 0.000 description 1
- 231100000003 human carcinogen Toxicity 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗肝炎药物,特别是涉及一种治疗肝类的舒肝止痛膏。由柴胡、黄芩、茵陈、穿山甲、鳖甲、三七、丹参、伏苓、大黄等有关中药,按一定比例破碎成一定粒度,放入定量植物油浸泡后入锅加热煎炸,待药枯油黑时,滤渣加入定量黄丹粉搅拌,待油温降低到150℃后,加入定量乳香,没药粉继续搅拌到药油不粘手离火,倾倒入水中浸泡后,按重量要求压成膏药。本发明开创肝炎内病外治先河,经临床观察疗效显著,使用方便,无副作用,价格低廉,能大大减轻患者负担。
Description
(一)技术领域:本发明涉及一种治病药膏。特别是涉及一种治疗肝炎(特别是乙肝、丙肝)的舒肝止痛膏。
(二)背景技术:肝炎是严重危害人类健康的常见传染病。目前已知的有甲型,乙型,丙型,丁型,戊型等五种类型肝炎。其中乙型肝炎是波及全世界的传染病,对人类健康危害之大,其流行范围之大,发病率之高,传染性之强,罹患人数之多,是其它传染病所不能比拟的。我国是肝炎患者大国,据有关资料介绍,全国6亿人感染过乙肝病毒,目前仍有约1.5亿人仍为乙肝病毒的携带者,其中有约3000万人确诊为乙肝患者,每年约有600多万人加入乙肝患者行列。乙肝为肝硬化的病因之一,约有30%的乙肝患者转为肝硬化,有86.7%的肝癌病人都有乙肝病史,在已知的人类致癌病人都有乙肝病史,在已知的人类致癌物质中,乙肝病毒被列为第二(仅次于烟草)。
近年来国内外对乙肝的诊断和治疗研究取得一定进展,出现了一些新药物。如被外国人推崇的干扰素(ZFH-a),在国内试用,效果不理想,其抑制HBV(乙肝病毒)复制作用有限,HbeAg/抗-Hbe血清转换率只有15%~30%,而且短期疗效差,停药后反弹率高;近期国内有人用草磷酸,阿糖腺莓(Ara-Amp)治疗HB取得一定效果,疗程结束时HbeAg阴转率为43.5%,但停药后同样有反弹,逾期疗程较差,Ara-Amp+胸腺肽或乙肝疫苗治疗HB,其中-Ara-Amp+胸腺肽作用较好,其HbeAg和HBVDNA阴转率为51.9%和42.3%,但随访资料较少,其总期疗效对肝组织HBV的副作用有待进一步验证。上述西药治疗乙肝反弹较严重,且药物价格昂贵,病人经济负担太重。
治疗肝炎也有用中药和中成药的。但用中药治疗肝炎病人很麻烦,熬药很费时间,并且喝汤时间长,容易伤胃,且药方一般缺乏标准化,疗程长,费时日,见效慢。
国内在专利申请和授权中出现有关的中成药治疗肝炎配方,如CN1094635,申请号为93111102.1一种治疗肝炎药物,用蜈蚣、甲珠、海金砂、白花蛇舌草,丹参、莪术等中草药按比例展成药粉,提取有效成份内服药;CN1156602,专利号:96105696.6,一种复方藏茵陈药,用柴胡,藏茵陈,枸杞子,红花,甘草按比例粉碎制成胶囊,片剂或口服液。CN110690申请专利号:94118275.4一种治疗肝炎药物,以淫羊藿,虎杖,赤芍,蒲公英,黄芪,广豆根,土茯苓等中草药制成药。上述治疗肝炎的专利技术中成药,目前未见进入市场销售,口服中成药或针剂中成药作用于再流经胃肠吸收再输送到血液,血液再流到肝脏时,才能产生治疗作用,所需时间长且不直接作用,针剂药也存在类似问题。所以寻找一种治疗简捷,无副作用,能直接作用于病灶区,见效快,疗效好的治疗肝炎药物在所必然。
(三)发明内容:本发明的目的是,开创肝炎内病外治的先河,提供一种具有清热解毒,舒肝利气,活血化瘀,化痞散结,消肿镇痛治疗肝炎的舒肝止痛膏,可以用来治疗甲肝,乙肝,丙肝,戊肝,肝硬化,脂肪肝,酒精肝,肝脓肿,肝癌,胆囊炎,胆结石,胆管炎的药物。
本发明的技术方案是:一种治疗肝炎的舒肝止痛膏,由有关中草药按一定比例配制,部分研磨成药粉,其余破碎或铡扎成粒状或短杆状,放入植物油中浸泡,然后倒入锅中加热煎炸,滤渣后加入有关药粉搅拌,形成药油膏,倒入水中浸泡,挤干水分,按重量要求压成药膏,以重量份为例,含有柴胡3~10,黄芩3~10,茵陈6~30,穿山甲1~15,鳖甲3~15,三七1~10,丹参5~15,茯苓10~60,大黄3~12,将其混均破碎放入植物油中浸泡,浸泡药量与植物油之比为1∶(2~3.5);将乳香3~10,没药3~10粉碎成药粉,黄丹与熬成药油之比为1∶(2~2.5),将浸泡草药和植物油一起入锅加热煎炸,待到药枯,油黑时,去渣加入黄丹粉搅拌,后再加入乳香,没药粉继续搅拌,制成药膏油,倒入水中浸泡后,挤去水分按重量要求分块压成舒肝止痛膏。
含有柴胡6~10,黄芩5~10,茵陈10~30,穿山甲5~10,鳖甲10~15,三七3~10,丹参10~15,茯苓10~30,大黄5~10,乳香5~10,没药5~10。
草药的破碎粒度为3~10mm左右,在植物油的浸泡时间为3~7天,草药煎炸到药枯油黑约40~60分钟,乳香粉,没药粉在药油温度小于150℃时加入,药膏重量为10克/张,15克/张,30克/张,50克/张,植物油可为菜籽油、黄豆油、花生油、棉籽油、葵花籽油、芝麻油或植物混合油等。
本发明有益积极结果:
本发明的舒肝止痛膏经河南省中医药研究院下属河南省针灸经络研究所30例各类肝病患者临床观察,并与对照组30例对比,治疗肝炎的舒肝止痛膏具有明显疗效。
在30例观察组中患有各种胁痛患者,病程1~20年,年龄在20~64岁,男19例,女11例,慢性肝炎6例,肝硬化8例,急性胆囊炎5例,慢性胆囊炎9例,其它2例,其治疗结果见下表。
观察组和对比组疗效对比表(%)
组别 | 例数 | 临床控制(治愈) | 显效 | 有效 | 无效 |
观察组 | 30 | 10(33.33) | 12(40.00) | 4(13.33) | 4(13.34) |
对照组 | 30 | 5(16.67) | 6(20.00) | 10(33.33) | 9(30.00) |
从上表可以看出,经一个疗程后,观察组临床控制率达到33.33%(即治愈不出现肋痛),总有效率达到86.66%,而对照组临床控制率达到16.67%,总有效率达70%,经统计处理差别有显著性差异(P<0.05),清楚表明使用舒肝止痛膏的观察组患者疗效明显优于对照组。
(2)舒肝止痛膏,经河南省防疫站检测:参照化学物质急性毒性分级标准判断,舒肝止痛膏急性经皮毒性属于实际无毒级;根据皮肤刺激强度评价判断,舒肝止痛膏(敷用4小时)对动物皮肤无刺激性。
(3)本发明的一个重要特点是开创了肝炎内病外治的先河,直接把膏药贴在肝脏处,便于拨毒,促进肝细胞生长,增加免疫功能,使用方便,其标准符合《中华人民共和国药典》二○○一年有关规定。
(4)本发明用纯天然植物药为原料,其组方符合我国药典有关规定,利用各味中草药治疗肝炎,对人体无毒副作用。
(5)本发明使用方便,携带方便,贮藏方便。舒肝止痛膏根据不同患者,药膏可直接贴于肝脏处,肚脐处,及肾脏处。
(6)本发明价格低廉,大大减轻肝病患者的经济负担。
(7)本发明对肝硬化,肝癌,乙肝,丙肝,戊肝,经治疗实践证明有显著疗效。
典型病例:
1.翟某,男,三十多岁,西安市某单位职工,有乙肝病史7年,肝硬化5年,98年9月出差,因腹泻引起肝硬化腹水,住西安某大医院,经专家多方医治,仍未能控制病情,经人介绍来诊病人腹大如鼓,不能平卧,脸色黎黑,下肢凹陷性水肿,精神萎顿,经用舒肝止痛膏贴肚脐,肝脏区及两肾区,加针灸辅助治疗,水肿逐渐消失,七天后腹胀基本消失,二十多天后,病人基本恢复正常,B超显示腹水肿全部消失,又连续贴用舒肝止痛膏一个半月,乙肝两对半检查全部转阴,使原给他治疗的西安某医院专家称奇。
2.华某,某研究所研究人员,96年身体感不适,浑身无力,面色萎黄,纳差,到医院检查,查出乙肝,服药治疗。97年因劳累,病情加重,人开始消瘦,肝区疼痛,随到医院检查,确诊为肝癌。贴舒肝止痛膏,几天后患者肝区好象有一股气一样东西在窜动,有往下拽的感觉,后大便开始出现粘冻一样东西,便次增多,半个月后大便出现脓血样东西。此情况持续二十天左右,贴药膏一个半月后,患者能上班,三个多月后,患者能参加单位文娱体育比赛,后CT检查,病灶已消失,乙肝三项转阴,抗-Hbs阳性,肝功能恢复正常,以后每年单位体检身体都正常。
3.江某,某单位化验员,因乳腺做手术输血而感染丙肝,贴舒肝止痛膏两个多月,经复查,肝功能氨酶由142降至38,乙肝两对半化验除表面抗阳性外皆转阴,患者身体基本恢复正常。
4.王某,50多岁,乙肝病史一年多,人消瘦,困乏无力,肝区疼痛,纳差,睡眠差,虽经多家医院治疗,症状未减轻,经人介绍,贴舒肝止痛膏,开始半信半疑,抱着本病无良医,先贴一贴试试看,谁知贴一个多月后,奇迹出现,肝区不痛,腰也不痛,饭量大增,睡觉很香,体力恢复,面色红润,贴了二个多月后,到医院检查,肝功能基本正常。
本发明从祖国医药宝库中筛选出清热解毒疏肝利气,消肿止痛,活血化瘀,祛瘀生新,化痞散结的中草药。方中的柴胡,是治疗肝病最常用的药。现代药理研究证明,柴胡含有柴胡皂甙、挥发油,生物碱等,具有解热,镇痛,抗菌消炎,保肝利胆作用,其抗菌作用与强地松相似。柴胡粗皂甙对实验性动物肝损害有显著抗损伤恢复,抗肝纤维化,对肝硬化有防治作用,使其肝硬化过程中减轻肝细胞坏死,防止肝脂肪性变,抑制纤维增生,并促进纤维吸收,临床证实,对慢性肝炎,肝脾肿大者使用柴胡制剂,可使肝脾回缩;黄芩含有黄芩甙,黄芩素,黄芩黄酮,对多种肝火均有降酶作用,并利胆退黄降絮降浊,有效率在79~90%之间,抑制乙肝病毒,实验证明,黄芩煎剂对HbeAg有较强抑制作用;茵陈现代研究具有利胆,保肝,抗菌作甩,临床应用上,用于清热解毒,护肝降酶菌陈烯能消除炎症,防止肝细胞坏死,促进肝细胞再生,促进肝内血液循环的作用;大黄具有抗癌作用,能降低胆固醇及甘油三酯,可用于治疗脂肪肝收敛止血,沉淀蛋白质作用,促进创伤面愈合,促进凝血;穿山甲有破血消积之功,常用肝脾肿大,肝硬化治疗,鳖甲具有滋阴退热,软坚散结之功,现代研究证明鳖甲具有抑制结缔组织增生,提高血浆蛋白作用,有提高机体免疫能力,延长抗体存在时间作用,适用于肝脾肿大,肝硬化;三七功主散瘀止血,消肿定痛,具有较好护肝降酶作用;茯苓主治水湿停聚,水肿胀满,胸胁痞满,现代药理研究证明茯苓具有利尿,抗菌,抗肿瘤作用。
本发明利用柴胡升清阳,黄芩降浊阴,茵陈能解毒,这一升一降一解,能调理转变阴阳升降之枢机,方中乳香,没药,黄丹,拨毒生肌,祛瘀生新,全方配伍共奏清热解毒,利湿退黄,消肿止痛,疏肝利气,化痞散结之功效。
(四)附图说明
图1:舒肝止痛膏结构示意图之一。
图2:舒肝止痛膏结构示意图之二。
(四)具体实施例
实施例一,参见图1,2,图中,1为圆形药膏,2为药膏托布,3为椭圆形药膏。
按下列配比取各种中草药原料,重量以千克为单位:柴胡9,黄芩8,茵陈30,穿山甲13,鳖甲15,三七6,丹参15,乳香6,没药6,茯苓30,大黄12。
生产方法:先将乳香,没药粉碎成药粉,过100目筛,其余的草药酌情粉碎为3~10mm粒度,放入芝麻油300公斤中浸泡7天,然后锅内加热煎炸,炸至药枯油黑,滴水成珠时去火,约40~60分钟滤去药渣,得药油约150公斤,取黄丹75公斤,将黄丹徐徐放入药油搅拌,试之药膏不粘手时,即离火,待油温降至150℃以下时,加入乳香,没药粉搅拌均匀,得药膏油237kg,倾入水中浸泡7天左右,捞出成块药膏除去水分,按10克/张,15克/张,30克/张切成块,再放到压膏药机上压成形,可得药膏23700张,或15800张,或7900张。
使用方法:先洗净患处皮肤,然后将膏药加热到不烫手为度,贴肚脐用10克/张圆形,贴双肾俞用15克/张椭圆形,贴肝脏用30克/张椭圆形。
实施例二:以公斤为单位,柴胡4,黄芩5,茵陈10,穿山甲3,鳖甲4,三七3,丹参6,茯苓12,大黄4,麻油116,乳香4,没药3,黄丹30。
生产方法同实施例一,不重述,得舒肝止痛膏约95公斤,可制药膏9500张,或6333张,或3166张。
实施例三:以公斤为单位柴胡10,黄芩10,茵陈28,穿山甲13,鳖甲15,三七9,丹参14,茯苓30,大黄10,乳香10,没药8,芝麻油314公斤,黄丹78.5公斤。生产方法同实施例一,不重述,得舒肝止痛膏约253.5公斤,可制药膏25350张,或16900张,或8450张。
Claims (3)
1.一种治疗肝炎的舒肝止痛膏,其特征在于它由以下方法制成:将柴胡3~10重量份、黄芩3~10重量份、茵陈6~30重量份、穿山甲1~15重量份、鳖甲3~15重量份、三七1~10重量份、丹参5~15重量份、茯苓10~60重量份、大黄3~12重量份混均破碎放入植物油中浸泡,浸泡药量与植物油之比为1∶2~3.5;将乳香3~10重量份、没药3~10重量份粉碎成药粉,黄丹与熬成药油之比为1∶2~2.5,将浸泡的草药和植物油一起入锅加热煎炸,等到药枯,油黑时,去渣加入黄丹粉搅拌,后加入乳香、没药粉继续搅拌,制成药膏油,倒入水中浸泡后,挤去水分按重量要求分块压成舒肝止痛膏。
2.根据权利要求1所述的舒肝止痛膏,其特征是:原料药为柴胡6~10,黄芩5~10,茵陈10~30,穿山甲5~10,鳖甲10~15,三七3~10,丹参10~15,茯苓10~30,大黄5~10,乳香5~10,没药5~10。
3.根据权利要求1或2所述的舒肝止痛膏,其特征是:草药的破碎粒度为3~10mm左右,在植物油的浸泡时间为3~7天,草药煎炸到药枯油黑约40~60分钟,乳香粉,没药粉在药油温度小于150℃时加入,药膏重量为10克/张,15克/张,30克/张,50克/张,植物油为菜籽油,或为黄豆油,花生油,棉籽油,葵花籽油,芝麻油或植物混合油。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021154678A CN1194722C (zh) | 2002-01-23 | 2002-01-23 | 治疗肝炎的舒肝止痛膏 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021154678A CN1194722C (zh) | 2002-01-23 | 2002-01-23 | 治疗肝炎的舒肝止痛膏 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1413620A CN1413620A (zh) | 2003-04-30 |
CN1194722C true CN1194722C (zh) | 2005-03-30 |
Family
ID=4743675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021154678A Expired - Fee Related CN1194722C (zh) | 2002-01-23 | 2002-01-23 | 治疗肝炎的舒肝止痛膏 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1194722C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101940771A (zh) * | 2010-09-04 | 2011-01-12 | 荣成市科学技术情报研究所 | 一种治疗病毒性肝炎肝硬化的中药 |
-
2002
- 2002-01-23 CN CNB021154678A patent/CN1194722C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1413620A (zh) | 2003-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103223131B (zh) | 肝病药物 | |
CN102698207A (zh) | 一种治疗肝病的中药组合物及其制备方法 | |
CN104435535B (zh) | 一种治疗ⅱ型糖尿病的保健药品 | |
CN1078081C (zh) | 治疗骨质增生、风湿、类风湿的药物及其制备方法 | |
CN1814215A (zh) | 一种治疗痛风及痛风性关节炎的药物 | |
CN1194722C (zh) | 治疗肝炎的舒肝止痛膏 | |
CN1215875C (zh) | 一种治疗骨折的口服纯中药散剂及其制备方法 | |
CN1879783A (zh) | 一种治疗糖尿病的药物 | |
CN103893611A (zh) | 一种治疗肾结石的药物及制备方法 | |
CN114712441A (zh) | 祛风活络喷雾剂及其制作方法 | |
CN1251751C (zh) | 一种治疗慢性肝病及抗肝纤维化的中药及其制备工艺 | |
CN104474103A (zh) | 一种天然植物降糖剂及其制备方法 | |
CN102327532B (zh) | 一种治疗风湿病、类风湿性关节炎胶囊 | |
CN102406906A (zh) | 一种治疗急性乙型肝炎的中药组合物 | |
CN102389545A (zh) | 一种治疗糖尿病痛风的中药 | |
CN100998720B (zh) | 一种治疗胞宫瘀滞型闭经的内服中药 | |
CN1927349A (zh) | 一种治疗痹症的中药及其制备方法 | |
CN1170571C (zh) | 一种治疗痔疮的药物及其制备方法 | |
CN1062765C (zh) | 益肝退黄药物 | |
CN100364573C (zh) | 一种治疗乙肝的中药 | |
CN118320028A (zh) | 中药组合物、制备方法及应用 | |
CN1686497A (zh) | 治疗性功能障碍、月经不调、不育症和增强免疫功能的中药制剂 | |
CN101095836B (zh) | 一种治疗慢性支气管炎的汤剂药物及制备方法 | |
CN101095837B (zh) | 一种治疗大便干结型慢性支气管炎的汤剂药物及制备方法 | |
CN103599185A (zh) | 一种用于治疗头痛的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050330 Termination date: 20150123 |
|
EXPY | Termination of patent right or utility model |